Tablets & Capsules Magazine

Definium Therapeutics (formerly MindMed) announced positive topline results from Panorama, the company’s second phase 3 study of DT120 orally disintegrating tablet (ODT) in adults with generalized anxiety disorder (GAD). Panorama met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline compared with placebo, as measured by the change in Hamilton Anxiety Rating Scale (HAM-A) total score at week 12.

As part of a rebranding effort called ‘Lasting Health Starts Now,’ Novo Nordisk is changing its name to simply ‘Novo.’ The rebrand is an effort to update the company culture ‘The Novo Way,’ and to gain a greater market share, which Novo describes as bringing "better health to many more people." There is an emphasis on seeing changes immediately, such as through ensuring breakthrough science leads to real results for consumers.

AstraZeneca’s oral SERD, Etcamah, in combination with a CDK 4/6 inhibitor, did not meet the primary endpoint of progression-free survival in a phase 3 trial of patients with ER-positive, HER2-negative advanced breast cancer. The SERENA-4 phase 3 trial evaluated Etcamah in combination with palbociclib versus treatment with an aromatase inhibitor (anastrozole) in combination with palbociclib.

Upon the release of positive results from its phase 3 CHAPTER-3 study, Pharvaris has announced that it will be submitting marketing authorizations for deucrictibant extended-release (XR) tablets in the first half of 2027. Deucrictibant XR is a prophylactic treatment hereditary angioedema (HAE) attacks.

The U.S. FDA has granted accelerated approval to AstraZeneca’s Etcamah, in combination with a CDK4/6 inhibitor, for 1st-line advanced HR-positive breast cancer.

Novartis has released phase 3 trial results for remibrutinib, showing that the oral drug significantly reduces annualized relapse rates in relapsing multiple sclerosis (RMS). Remibrutinib is a high-efficacy, highly-selective, potent Bruton’s tyrosine kinase (BTK) inhibitor. It modulates immune regulatory networks and neuroinflammation by preventing the activation of B cells and innate immune cells. It received FDA approval in September 2025 as Rhapsido for adults with chronic spontaneous uticaria.

AstraZeneca announced the successful completion of an exclusive license agreement with Shanghai-based Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. The deal, previously announced in July, gives AstraZeneca the worldwide rights to develop and commercialize Zegfrovy.

Gilead Sciences has received FDA approval for Bixlenvo, a once-daily single tablet HIV treatment for virologically-suppressed adults. The regimen is a combination of 75 mg bictegravir and 50 mg lenacapavir. Bictegravir is a guideline-recommended integrase strand transfer inhibitor (INSTI) with high barrier resistance, while lenacapavir is a first-in-class capsid inhibitor with no cross-resistance to other antiretrovirals.

The U.S. FDA has approved Tivicay PD (dolutegravir (DTG)), an oral medication from ViiV Healthcare for young children living with HIV, to be used in combination with other antiretroviral agents. The second-generation integrase strand transfer inhibitor (INSTI) has a higher barrier to resistance than previous generations. Available in tablets for oral use and for oral suspension, it is the first of its kind available to pediatric patients.

CDMO Hovione has completed the expansion of its tablet development and manufacturing center at its main global campus in Loures, Portugal. The expansion, which has cost the company a total of €40 million ($46 million), increases the manufacturing area by 25%, creating 50 skilled jobs. It includes an increase in batch tableting capacity through line mirroring across dispensing, blending, dry granulation, and tableting and film coating.